Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Cytokine1 who wrote (4228)	3/4/1998 12:20:00 AM
From: CYBERKEN	Respond to of 9719

Seems like the Street's firing squads are running out of bullets on AMLN. J&J walked away today (no surprise) and the stock crashed (again). I happened to be mostly out last summer when they screwed up the pramlintide trials and this all began. Stock's now 2-and-change. What's interesting is that pramlintide will most likely be a successful Type I diabetes treatment in 2 or three years, and still has potential for Type II. SO: 1)I'd expect a large biotech or pharm to try to get it, perhaps by buying AMLN. If SMTG purchase is any indication, an AMLN buyout in the next several months could be significantly higher than current price. 2) If AMLN could get another partner in next few months, they could be back at 5 to 7. All very speculative at this point. If they stay alive, I'd like to see what new mgt team is like.